Related Experiment Video

Updated: Jun 26, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Individual SGLT-2 Inhibitors and Risk of New-Onset Cancer in Type 2 Diabetes: A Nationwide Population-Based Cohort

Hayeon Kim1, Jun-Ho Seo2,3, Jin Hyun Nam4

  • 1College of Pharmacy, Korea University, Sejong, Korea.

Cancer Research and Treatment
|June 24, 2026
PubMed
Abstract

Insights

Sodium-glucose cotransporter-2 inhibitors (SGLT-2is), like empagliflozin and dapagliflozin, did not significantly alter new-onset cancer risk in type 2 diabetes patients. This real-world data suggests SGLT-2 inhibitors do not increase cancer incidence in this population.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Preclinical data suggested potential cancer-preventive effects of SGLT-2 inhibitors.
  • Clinical evidence regarding SGLT-2 inhibitors and cancer risk in type 2 diabetes patients remains inconclusive.
  • This study addresses the need for clinical data on SGLT-2 inhibitors (empagliflozin, dapagliflozin) and cancer incidence.

Purpose of the Study:

  • To evaluate the association between SGLT-2 inhibitor use (empagliflozin or dapagliflozin) and new-onset cancer incidence.
  • To compare cancer risk between SGLT-2 inhibitor users and users of other glucose-lowering drugs in type 2 diabetes patients.
  • To investigate the incidence of site-specific cancers in relation to SGLT-2 inhibitor use.

Main Methods:

  • Nationwide retrospective cohort study utilizing Korean national health claims data (2016-2019).
  • Inclusion of type 2 diabetes patients initiating empagliflozin, dapagliflozin, or other glucose-lowering drugs (oGLDs).
  • Propensity score matching was employed to create comparable cohorts; Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and confidence intervals (CIs).

Main Results:

  • After propensity score matching, 20,456 patients were in each group (SGLT-2i users vs. oGLDs users).
  • No significant difference in overall cancer incidence was observed for empagliflozin (aHR 0.85, 95% CI 0.65-1.12) or dapagliflozin (aHR 0.87, 95% CI 0.66-1.14) compared to oGLDs.
  • Incidence of site-specific cancers and comparisons between empagliflozin and dapagliflozin users also showed no significant differences, consistent across subgroup and sensitivity analyses.

Conclusions:

  • Empagliflozin and dapagliflozin use was not associated with a significant difference in new-onset cancer incidence in patients with type 2 diabetes.
  • These real-world findings provide clinical evidence regarding SGLT-2 inhibitor use and cancer risk in this patient population.
  • Further long-term follow-up studies are recommended to strengthen the validity of these results.
Keywords:
DapagliflozinDiabetes MellitusEmpagliflozinIncidenceNeoplasmsSodium-glucose transporter 2 inhibitorsType 2

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...